Ovarian cancer survival and chemotherapy dosing, body mass index, and body surface area : Are we there yet?
Menée sur 806 patientes atteintes d'un cancer primitif invasif de l'épithélium ovarien diagnostiqué entre 2000 et 2013, cette étude évalue, en fonction de l'indice de masse corporelle, l'effet de la dose de chimiothérapie administrée sur la survie des patientes, puis identifie les facteurs prédictifs associés à la mortalité spécifique
The study in this issue of JAMA Oncology by Bandera et al1 evaluated the association of body mass index (BMI) and chemotherapy dosing, and the authors related relative dose intensity (RDI) to overall and ovarian cancer–specific mortality. This retrospective cohort analysis was based on the Kaiser Permanente Research on Ovarian Cancer Study of Epithelial Ovarian Cancer chemotherapy subcohort (806 patients). Importantly, it is a relatively unselected real-world cohort, and one of the largest studied to date. The investigators concluded that lower RDI of paclitaxel and carboplatin was associated with diminished survival in women treated for ovarian cancer, which further confirms observations by others.
JAMA Oncology , éditorial en libre accès, 2014